NICE Continues to Support Patient Access to Innovative Treatments | Blog | New

NICE is committed to helping the health and care system bring innovation to patients earlier, at a price that the taxpayer can afford. So I’m delighted to join a panel of experts to participate in a King’s Fund event next week. The event, which is titled ‘Innovation in medicines: adapting for the future’, will explore how the system can work together to get the most out of innovation, while maintaining patient safety and clinical standards.

As I prepared for the event, I once again had the opportunity to reflect on how much the world has changed since NICE was founded 22 years ago. How we face and must continue to meet new challenges in order to preserve the rigor and quality of decisions, while responding to the pace of frankly enormous changes that we are witnessing in the field of health and social services.

I think we need to adapt to this new landscape and make the most of scientific research, which has never been as promising as it is today, to collectively harness new and exciting possibilities to fight disease through development. of innovative drugs. Continued collaboration across the system remains vital, in order to navigate these developments and provide patients with access to innovative, life-changing and saving treatments.

Take for example the Innovative Licensing and Access Pathway (ILAP) – of which NICE is a main partner. ILAP aims to accelerate patient access to safe and innovative medicines in the UK and is offered in partnership by the All Wales Therapeutics and Toxicology Center, the Medicines and Health Products Regulatory Agency (AWTTC) , NICE, Medicines and Healthcare

the Health Products Regulatory Agency (MHRA) and the Scottish Medicines Consortium (SMC), part of Health Improvement Scotland.

This initiative is a prime example of something that could lead to the provision of rapid, robust and responsive technology assessment that aims to provide patients with safe, early and financially sustainable access to medicines. It gives us the opportunity to think and practice differently after leaving the European Union and it is a truly exciting development with the potential for major benefits for patients, the NHS and the life sciences industry. . For NICE, this also gives us a fantastic opportunity to build on other initiatives, such as our coordination of the very successful Research to Access Pathway for Investigational Drugs for COVID-19 (RAPID C-19). ILAP is also supporting Project Orbis, a program coordinated by the United States Food and Drug Administration (FDA), which aims to examine the approval of promising cancer treatments around the world. The MHRA became a full partner in this program in January 2021, and I am excited to see the impact this could continue to have in allowing partners to review and approve requests for promising treatments for the disease. Cancer. While it is relatively early on with these initiatives, I believe they allow, with the new Innovative Medicines Fund (IMF) in the UK, to link licensing and access more effectively in order to provide the most innovative drugs to patients more quickly. .

I hope many of you can join us for the King’s Fund event, I am sure it will be a rewarding and interesting discussion.

My fellow panellists at the event are:

  • Paula Head, Senior Fellow, The King’s Fund (chair)
  • Lord Bethell of Romford, Parliamentary Under Secretary of State (Minister for
  • Innovation)
  • Nick Meade, Acting Managing Director and Policy Director, Genetic Alliance UK
  • Dr Olivia Rossanese, Acting Director of Cancer Research UK Cancer Therapeutics
  • Unit and Acting Head of the Cancer Therapeutics Division, Cancer Institute
  • Research
  • Paul Catchpole, Director of Value and Access, ABPI

If you wish to join us, registration is free via the following link Innovation in Medicines | The King’s Fund (kingsfund.org.uk)


Source link

Leave a Reply

Your email address will not be published.